Arvinas (ARVN) Operating Expenses (2017 - 2026)
Arvinas' (ARVN) quarterly Operating Expenses came in at $79.4 million in Q1 2026, down 32.37% year-on-year from $117.4 million in Q1 2025, and down 5.59% quarter-over-quarter from $84.1 million in Q4 2025.
Arvinas (ARVN) Operating Expenses (2017 - 2026) Analysis & Trends
Arvinas' Operating Expenses history runs 10 years deep, the most recent figure standing at $79.4 million for Q1 2026.
- On a quarterly basis, Operating Expenses fell 32.37% year-over-year to $79.4 million in Q1 2026; TTM through Mar 2026 was $343.1 million, a 34.33% decrease from a year earlier, with the FY2025 full-year figure at $381.1 million, down 25.8% from the prior year.
- Operating Expenses declined to $79.4 million in Q1 2026 per ARVN's latest filing, from $84.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $162.7 million in Q3 2024 and bottomed at $79.4 million in Q1 2026.
- The 5-year median for Operating Expenses is $108.6 million (2024), against an average of $108.8 million.
- Across the five-year window, Operating Expenses soared 78.39% in 2022 and tumbled 47.33% in 2025, its largest moves.
- Year by year, Operating Expenses stood at $113.4 million in 2022, then grew by 7.76% to $122.2 million in 2023, then decreased by 3.93% to $117.4 million in 2024, then dropped by 28.36% to $84.1 million in 2025, then decreased by 5.59% to $79.4 million in 2026.
- Per Business Quant, the three latest ARVN Operating Expenses figures stand at $79.4 million (Q1 2026), $84.1 million (Q4 2025), and $85.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -28.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.10 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.78 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.85 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 2.89 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 445.22 Mn |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | 79.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79.40 Mn |
| Dec 31, 2025 | 84.10 Mn |
| Sep 30, 2025 | 85.70 Mn |
| Jun 30, 2025 | 93.90 Mn |
| Mar 31, 2025 | 117.40 Mn |
| Dec 31, 2024 | 117.40 Mn |
| Sep 30, 2024 | 162.70 Mn |
| Jun 30, 2024 | 125.00 Mn |
| Mar 31, 2024 | 108.60 Mn |
| Dec 31, 2023 | 122.20 Mn |
| Sep 30, 2023 | 108.50 Mn |
| Jun 30, 2023 | 129.10 Mn |
| Mar 31, 2023 | 120.20 Mn |
| Dec 31, 2022 | 113.40 Mn |
| Sep 30, 2022 | 97.50 Mn |
| Jun 30, 2022 | 99.60 Mn |
| Mar 31, 2022 | 84.20 Mn |
| Dec 31, 2021 | 80.70 Mn |
| Sep 30, 2021 | 56.60 Mn |
| Jun 30, 2021 | 57.40 Mn |